CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries

Core Insights - CAMP4 Therapeutics has entered a strategic collaboration with GSK to develop antisense oligonucleotide (ASO) drug candidates targeting neurodegenerative and kidney diseases, leveraging CAMP4's RAP Platform [1][4][5] Financial Terms - CAMP4 will receive an upfront payment of $17.5 million and is eligible for additional milestone-based payments and tiered royalties on future product sales [3][1] Collaboration Details - The collaboration aims to identify and develop ASO candidates that increase the expression of validated genetic targets, addressing the critical role of protein under-expression in diseases [2][5] - GSK will handle the further development and commercialization of the ASO drug candidates identified through this partnership [4] Technology and Approach - CAMP4's RAP Platform is designed to identify regulatory RNAs (regRNAs) that control gene expression, enabling the generation of ASO candidates that amplify target gene expression [4][6] - The company focuses on amplifying mRNA to develop disease-modifying treatments for over 1,200 genetic diseases where increased protein expression may provide therapeutic benefits [6]